Data Sheet (Cat.No.T7179)

TargetMol

Garenoxacin

Chemical Properties



CAS No. : 194804-75-6

Formula: C23H20F2N2O4

Molecular Weight: 426.41

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Garenoxacin (BMS284756) is a novel oral des-fluoro(6) quinolone for the treatment of Gram-positive and Gram-negative bacterial infections.
Targets(IC50)	Antibacterial,Antibiotic,DNA/RNA Synthesis,Topoisomerase
In vivo	The mean maximum plasma concentration (Cmax) was 3.00 ± 1.12 μg/mL, time to maximum plasma concentration (Tmax) was 3.0 ± 2.0 hours, and area under the curve for 24 hours (AUC0-24) was 40.7 ± 16.7 μg·h/mL. The half-life (T1/2) of GRNX could not be calculated because plasma concentrations remained high 24 hours after administration. Cmax was strongly associated with the GRNX dose per kilogram body weight (r = 0.85, P = 0.03).Clinically, fever resolved within 3 days of GRNX administration and C-reactive protein levels returned to normal 14 days after administration. One patient experienced temporary increases in serum transaminase levels[1].
Animal Research	Six male patients with infections who were undergoing MH received 200 mg GRNX once daily. Blood samples were taken before and at 1, 2, 4, 6, 12, and 24 hours after GRNX administration. Plasma GRNX concentrations were measured using high-performance liquid chromatography[1].

Solubility Information

Solubility	DMSO: 2 mg/mL (4.69 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3452 mL	11.7258 mL	23.4516 mL
5 mM	0.469 mL	2.3452 mL	4.6903 mL
10 mM	0.2345 mL	1.1726 mL	2.3452 mL
50 mM	0.0469 mL	0.2345 mL	0.469 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Aoyama T , Kamata K , Kishino S . Garenoxacin pharmacokinetics in patients undergoing maintenance hemodialysis[J]. Hemodialysis International, 2016.

Yuka Y , Tatsuya S , Satoshi N , et al. Proposed Pharmacokinetic-Pharmacodynamic Breakpoint of Garenoxacin and Other Quinolones[J]. Japanese Journal of Infectious Diseases, 2017, 70(6):616-620.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481